Challenges and Opportunities in Pharmaceutical Manufacturing

The rapid change in demand for pharmaceutical products during the COVID-19 pandemic sent shockwaves throughout the industry. Since the start of the crisis, pharma manufacturers have implemented a number of innovations to streamline the production process from start to finish....

5 years ago
Biomanufacturing,Biology

Challenges and Opportunities in Pharmaceutical Manufacturing

The rapid change in demand for pharmaceutical products during the COVID-19 pandemic sent shockwaves throughout the industry. Since the start of the crisis, pharma manufacturers have implemented a number of innovations to streamline the production process from start to finish....

5 years ago

Latest Advancements in Parkinson’s Treatment: CGT Shows Potential to Reverse Disease

Every hour, two more people are diagnosed with Parkinson’s in the UK and the global patient population continues to rise. To date, there are no disease-modifying therapies available on the market for Parkinson's (PD) patients. Pharmaceutical company Bayer is simultaneously...

5 years ago
CGT,Clinical Development,News

Latest Advancements in Parkinson’s Treatment: CGT Shows Potential to Reverse Disease

Every hour, two more people are diagnosed with Parkinson’s in the UK and the global patient population continues to rise. To date, there are no disease-modifying therapies available on the market for Parkinson's (PD) patients. Pharmaceutical company Bayer is simultaneously...

5 years ago

Vaccines and Variants: How Do They Work?

As of 23 June 2021, there are 14 variants of COVID-19 which are of concern or under investigation in the UK, according to the UK government. The unique profile of COVID-19 enables rapid mutation, producing variants which are more transmissible...

5 years ago
R&D,Biology,News

Vaccines and Variants: How Do They Work?

As of 23 June 2021, there are 14 variants of COVID-19 which are of concern or under investigation in the UK, according to the UK government. The unique profile of COVID-19 enables rapid mutation, producing variants which are more transmissible...

5 years ago

Strategies Implemented for New Modalities of Therapeutic Targeting: ASOs and RNAi

In 2018, the FDA approved the first small interfering RNA (siRNA) drug, patisiran, to treat a disease known as hereditary transthyretin amyloidosis. Since then, an increasing number of oligonucleotide-based drugs have reached the market, showing advantages over small molecule drugs....

5 years ago
R&D,Bioprocess,Biology,News

Strategies Implemented for New Modalities of Therapeutic Targeting: ASOs and RNAi

In 2018, the FDA approved the first small interfering RNA (siRNA) drug, patisiran, to treat a disease known as hereditary transthyretin amyloidosis. Since then, an increasing number of oligonucleotide-based drugs have reached the market, showing advantages over small molecule drugs....

5 years ago

Using Translational Research to Bridge the Gap Between Preclinical and Clinical Research

The disparity between animal models and clinical efficacy is compromising the safety and efficacy of therapeutic drugs. Translational research is building the bridge between preclinical studies and therapeutic treatment. Genomic techniques and non-traditional animal models are examples of translational approaches...

5 years ago
R&D,Clinical Development,Clinical Operations,Biology,News

Using Translational Research to Bridge the Gap Between Preclinical and Clinical Research

The disparity between animal models and clinical efficacy is compromising the safety and efficacy of therapeutic drugs. Translational research is building the bridge between preclinical studies and therapeutic treatment. Genomic techniques and non-traditional animal models are examples of translational approaches...

5 years ago

Moving Towards Phenotypic Screening in Drug Discovery: An Interview with Prasun Mishra

Despite the technological advances, drug discovery is still a lengthy, expensive, and difficult stage in the drug development process. Screening assays are a critical part of rapidly and thoroughly analysing vast numbers of compounds for desired biochemical activity. In a...

5 years ago
R&D,Biology,News

Moving Towards Phenotypic Screening in Drug Discovery: An Interview with Prasun Mishra

Despite the technological advances, drug discovery is still a lengthy, expensive, and difficult stage in the drug development process. Screening assays are a critical part of rapidly and thoroughly analysing vast numbers of compounds for desired biochemical activity. In a...

5 years ago
Previous Page Showing 180 out of 323 Next Page
Working With us

Interested?
Reserve your space